Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Creo Medical Group's Debt-to-EBITDA or its related term are showing as below:
CMEOF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.57 Med: -0.25 Max: 0
Current: -0.25
CMEOF's Debt-to-EBITDA is ranked worse than 100% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs CMEOF: -0.25
Creo Medical Group (OTCPK:CMEOF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Creo Medical Group Debt-to-EBITDA Related Terms
Creo Medical Group Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Creo Medical Group's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Creo Medical Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creo Medical Group Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Creo Medical Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Creo Medical Group (CMEOF) has a Debt-to-EBITDA of -0.06 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Creo Medical Group. According to the industry distribution chart, Creo Medical Group ranks #999999 out of 467 companies in the Medical Devices & Instruments industry.
Is Creo Medical Group's Debt-to-EBITDA too high?
Creo Medical Group's current Debt-to-EBITDA is -0.06. Based on the distribution chart, Creo Medical Group ranks #999999 out of 467 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Creo Medical Group has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Creo Medical Group ranks #999999 out of 467 companies for Debt-to-EBITDA. This places Creo Medical Group in the lower half of its industry. The industry median Debt-to-EBITDA is 1.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.57, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Creo Medical Group. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creo Medical Group's current Debt-to-EBITDA is -0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Creo Medical Group (CMEOF) has a current Debt-to-EBITDA of -0.06. The stock's GF Value™ is $0.26, compared to a current price of $0.23 — trading 13.2% below its estimated fair value. The current Debt-to-EBITDA is -0.06. Creo Medical Group's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current Debt-to-EBITDA is -0.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creo Medical Group (CMEOF) Overvalued in 2026?
Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued.
The current stock price of $0.23 is trading 13.2% below its estimated GF Value™ of $0.26.
Key valuation signals for CMEOF:
Debt-to-EBITDA: -0.06
GF Value™: $0.26 vs. price of $0.23 (13.2% below fair value)
No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
52GF Score
Get the complete analysis for CMEOF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMEOF has been successfully added to your 
